Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Dolastatin-10. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | CTSE | P14091 | 6/20 | 0.32 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolastatin-10 SCHEMBL18793204 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13135112 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL12016480 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL5286 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13378458 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL23387006 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL6423272 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126284 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126283 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL14583139 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903948-B2 | Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-02-20 | — | — | US | disclosed |
| US-20230293536-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20220008553-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-01-13 | — | — | US | disclosed |
| US-20210252006-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20190076438-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2019-03-14 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | SSTR2 1821/4885CYP3A4 102/4885FOLH1 22/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | SSTR2 1821/4885CYP3A4 102/4885FOLH1 22/4885 |
| US-20190076438-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ERBB2, ERBB3, EGFR | SSTR2 1906/4885CYP3A4 1508/4885FOLH1 164/4885 |
| US-20230293536-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ERBB2, ERBB3, EGFR | SSTR2 1866/4885CYP3A4 1545/4885FOLH1 168/4885 |
| US-11903948-B2 | Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof | ERBB2, EGFR, ERBB3 | SSTR2 1139/4885CYP3A4 2599/4885FOLH1 801/4885 |
| US-20210252006-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | ERBB2, EGFR, ERBB3 | SSTR2 1139/4885CYP3A4 2599/4885FOLH1 801/4885 |
| US-20220008553-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | ERBB2, EGFR, ERBB3 | SSTR2 1359/4885CYP3A4 3210/4885FOLH1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.